Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205)

PURPOSE: Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection. Because cetuximab enhances the effect of radiat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Garg, Madhur K., Zhao, Fengmin, Sparano, Joseph A., Palefsky, Joel, Whittington, Richard, Mitchell, Edith P., Mulcahy, Mary F., Armstrong, Karin I., Nabbout, Nassim H., Kalnicki, Shalom, El-Rayes, Bassel F., Onitilo, Adedayo A., Moriarty, Daniel J., Fitzgerald, Thomas J., Benson, Al B.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455423/
https://ncbi.nlm.nih.gov/pubmed/28068178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.69.1667
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares